Comparison · NCT05059262-sae
Total - Vimseltinib vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Total - Vimseltinib vs Placebo: serious adverse events. Trial comparisons, record NCT05059262-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05059262-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.144 | 0.0919 | 0.219 | wilson | |
| Risk in group 2 | 0.0256 | 0.00454 | 0.132 | wilson | |
| Risk difference, group 1 minus group 2 | 0.118 | 0.000149 | 0.196 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 5.62 | 0.773 | 40.9 | log | |
| Odds ratio, group 1 over group 2 | 6.4 | 0.823 | 49.7 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Total - Vimseltinib than on Placebo | 8.44 | 5.1 | 6,710 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Total - Vimseltinib | Participants received blinded treatment of vimseltinib 30 mg BIW for 24 weeks in Part 1 and/or open-label vimseltinib 30 mg BIW in Part 2 until EoT. | 17 | 118 | EG000 |
| Group 2 | Placebo | Participants received blinded treatment of matching placebo BIW for 24 weeks. | 1 | 39 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Collection of adverse events started from the signing of informed consent through safety follow-up (up to 1.68 years)
Source ClinicalTrials.gov
Trial
- Title
- Study of Vimseltinib for Tenosynovial Giant Cell Tumor
- NCT number
- NCT05059262
- Phases
- PHASE3
- Conditions
- Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
- Interventions
- Vimseltinib, Placebo
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Results first posted
- 2025-02-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05059262?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05059262-sae